Todos Medical - Full Color Logo
  • R&D Pipeline
    • Proprietary Diagnostics
      • Videssa® Breast: Cancer Blood Test
      • LymPro™: Alzheimer's Blood Test
      • TolloTest™: Coronavirus 3CL Protease Test
      • TBIA: AI Cancer Platform
    • Antiviral Drug Development
      • Tollovir™: 3CL Protease Inhibitor
  • Products & Services
    • Lab Solutions
      • Provista Diagnostics: CLIA/CAP Lab
      • COVID Testing: Lab Supplies & Automated Solutions
    • Dietary Supplement
      • Tollovid™: 3CL Protease Inhibitor
  • Insights
    • Publications
    • News & Media
    • Downloads
    • How It Works: 3CL Protease Inhibitors
    • Case Study: Lab Automation
  • Investors
  • About
    • Management Team
    • Board of Directors
    • Advisors
    • Career Opportunities
    Add a button link here
    Contact Us

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Governance Documents
    • News & Events

    • Press Releases
    • IR Calendar
    • Email Alerts
    Mar 08, 2022 9:53am EST

    Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs

    Jan 27, 2022 8:23am EST

    Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

    Jan 24, 2022 8:34am EST

    Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

    Jan 19, 2022 8:00am EST

    Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®

    Jan 18, 2022 10:52am EST

    Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

    Jan 12, 2022 9:56am EST

    Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

    Jan 10, 2022 2:06pm EST

    Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

    Jan 05, 2022 6:04pm EST

    Todos Medical CEO Provides Letter to Shareholders

    Jan 03, 2022 8:30am EST

    Todos Medical to Present at January 5, 2022 Emerging Growth Conference

    Dec 27, 2021 9:01am EST

    Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

    • arrow_back
    • 1…
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • …25
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Company Profile
    • Contacts
    • RSS News Feed

    Todos Medical - Full Color-1

     

    About Us

    Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.

    OTCQB: TOMDF

    Contact Us

    Todos Medical Ltd.
    121 Derech Menachem Begin

    30th Floor
    Tel Aviv, Israel 6701203
    Phone: +972-73-207-7259

    Todos Medical U.S.A.
    40 Wall Street, Suite 2702

    New York, NY 10005
    Phone: +1-917-983-4229

    Sign Up

    Follow us on Twitter Follow us on Facebook Follow us on LinkedIn
    © 2023 Todos Medical. All rights reserved.